Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy
Annals of Clinical and Translational Neurology · 2024-04 · 11 (4) · 1059-1062
DOI: 10.1002/acn3.52010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 28.01.2024. Verfasst von Vanessa L Hull und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, UC Davis School of Medicine, Sacramento, California, USA. Hauptthemen laut MEDLINE: Canavan Disease, Neurodegenerative Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Canavan disease is a leukodystrophy caused by ASPA mutations that diminish oligodendroglial aspartoacylase activity, and is characterized by markedly elevated brain concentrations of the aspartoacylase substrate N‐acetyl‐ l ‐aspartate (NAA) and by astroglial and intramyelinic vacuolation. Astroglia express NaDC3 (encoded by SLC13A3 ), a sodium‐coupled transporter for NAA and other dicarboxylates. Astroglial conditional Slc13a3 deletion in aspartoacylase‐deficient Canavan disease model mice (“CD mice”) reversed brain NAA elevation and improved motor function. These results demonstrate that astroglial NaDC3 contributes to brain NAA elevation in CD mice, and suggest that suppressing astroglial NaDC3 activity would ameliorate human Canavan disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, UC Davis School of Medicine, Sacramento, California, USA.
- Shriners Hospital for Children, Sacramento, California, USA.
- Department of Physiology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
- Department of Biological Sciences, Kent State University, Kent, Ohio, USA.
ORCID-Profile: Vanessa L Hull, Jennifer McDonough, David Pleasure
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Institutes of Health
- Shriners Hospitals for Children
Zitieren
APA
Hull, V. L., Wang, Y., McDonough, J., Zhu, M., Burns, T., Al Ramel, N., Dehghani, A., Guo, F., & Pleasure, D. (2024). Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy. Annals of Clinical and Translational Neurology, 11(4), 1059-1062. https://doi.org/10.1002/acn3.52010
Vancouver
Hull VL, Wang Y, McDonough J, Zhu M, Burns T, Al Ramel N, et al. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy. Annals of Clinical and Translational Neurology. 2024;11(4):1059-1062. doi:10.1002/acn3.52010
BibTeX
@article{Hull2024,
author = {Hull, Vanessa L and Wang, Yan and McDonough, Jennifer and Zhu, Meina and Burns, Travis and Al Ramel, Najmah and Dehghani, Ali and Guo, Fuzheng and Pleasure, David},
title = {Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy},
journal = {Annals of Clinical and Translational Neurology},
year = {2024},
volume = {11},
number = {4},
pages = {1059--1062},
doi = {10.1002/acn3.52010}
}
EUVIMED